Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...

Checkpoint inhibitors are antibody-based cancer therapies that unlock the immune system’s natural ability to fight cancer. These treatments work by blocking special proteins called immune checkpoints, ...

3D rendering of a checkpoint inhibitor binding PD-1, a protein on the surface of an immune T cell. This article is part of an ongoing series on checkpoint inhibitors, a novel cancer immunotherapy.

Immune checkpoint inhibitors have significantly improved survival for a variety of malignancies over the past decade, but the costs of these medications have barely changed.An investigation into 11 ...

Please provide your email address to receive an email when new articles are posted on . Patients who received PD-1 or PD-L1 agents exhibited increased risk for psoriasis. Medical professionals should ...

Cancer researchers have chased the idea of a universal cancer vaccine for decades. The promise sounds bold and almost ...

Researchers at the University of Sharjah are exploring a promising approach that could enhance the immune system's ability to ...

MSI-H mCRC patients receiving ICIs had significantly improved OS compared to chemotherapy, with a 63% improvement in survival. MSS patients with high albumin levels or recent antibiotic use also ...

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune checkpoint inhibitors. These treatments, which ...